Highlights:
-- 2QFY23 Product Sales (unaudited) increased 27% qoq and 71% yoy to US$5.6m
-- Direct channel Product Sales increased 50% qoq and 258% yoy to US$4.3m
-- 1HFY23 Unaudited Product Sales increased 92% yoy to $10.0m
-- Wound Care prescribers increased 85% qoq to 819
-- XPERIENCE™ direct Product Sales increased 8% qoq and 58% yoy
-- Record cash receipts for 2QFY23 increasing 40% qoq and 140% yoy to US$5.3m
-- Cash on hand for 30 June was US$3.5m
-- Payments to Directors US$173k
Sydney Australia Thursday, 27 July 2023: Next Science Limited (ASX: NXS) (Next Science), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, is pleased to provide an update on its activities for the quarter ended 30 June 2023.
For more information, download the attached PDF.
Download this document
